Gene · 5144
PDE4D: phosphodiesterase 4D
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PDE4D: phosphodiesterase 4D. Genes, record 5144. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5144
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q08499 | 3',5'-cyclic-AMP phosphodiesterase 4D | 809 | 122 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 57738 | Q08499 | Espacenet |
| WO 2025252547 A1 | 2025-12-11 | 100 | Q08499 | Espacenet |
| EP 4660322 A1 | 2025-12-10 | 100 | Q08499 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6847 | Q08499 | Espacenet |
| WO 2025195968 A1 | 2025-09-25 | 11 | Q08499 | Espacenet |
| EP 4620461 A1 | 2025-09-24 | 11 | Q08499 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6847 | Q08499 | Espacenet |
| JP 2025081323 A | 2025-05-27 | 15 | Q08499 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 33156 | Q08499 | Espacenet |
| WO 2025016918 A1 | 2025-01-23 | 100 | Q08499 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs32
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMINOPHYLLINE | CHEMBL1370561 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| AMLEXANOX | CHEMBL1096 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| APREMILAST | CHEMBL514800 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| CILOMILAST | CHEMBL511115 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| CRISABOROLE | CHEMBL484785 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DIFAMILAST | CHEMBL3989968 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DIPYRIDAMOLE | CHEMBL932 | 3',5'-cyclic phosphodiesterase inhibitor | INHIBITOR | ChEMBL |
| DOVRAMILAST | CHEMBL4297460 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DROTAVERINE | CHEMBL551978 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
| DYPHYLLINE | CHEMBL1752 | Phosphodiesterase 4 inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 32
See all 32 drugsTrials540
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07566351 | ROFLUMILAST | PHASE2 | ClinicalTrials.gov | |
| NCT07543640 | ROFLUMILAST | PHASE2 | ClinicalTrials.gov | |
| NCT07537751 | CRISABOROLE | ClinicalTrials.gov | ||
| NCT07519174 | CRISABOROLE | ClinicalTrials.gov | ||
| NCT07438509 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07437534 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07398651 | APREMILAST | ClinicalTrials.gov | ||
| NCT07367932 | CRISABOROLE | PHASE4 | ClinicalTrials.gov | |
| NCT07366268 | APREMILAST | ClinicalTrials.gov | ||
| NCT07349472 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 540
See all 540 trialsNIH grants1,937
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PDE4D papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 6 | 2025 |
| P30ES007048 | Environmental Exposures, Host Factors and Human Disease | 6 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 6 | 2025 |
| R01HL016037 | Molecular Regulation of Cardiovascular 7 TM Receptors | 5 | 2025 |
| T32HL007427 | SYSTEMS APPROACHES TO THE EPIDEMIOLOGY, GENETICS AND GENOMICS OF LUNG DISEASES | 5 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 4 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 4 | 2025 |
| R01DK073368 | Mechanisms of Compartmentalized cAMP Signaling | 4 | 2025 |
1 to 10 of 1,937Source NIH's project files
See all 1,937 nih grantsPapers2,257
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epitranscriptomic Regulation of Cardiac Ischemia-Reperfusion Injury: Unveiling the METTL14/IGF2BP1/PDE4D Axis. | Korean Circ J | 2026 | 42750131 | PubTator, text mining | PubMed |
| [Clinical and genetic characteristics of 6 children with acrodysostosis]. | Zhonghua Er Ke Za Zhi | 2026 | 42742022 | PubTator, text mining | PubMed |
| Serum N-terminal Pro-B-Type Natriuretic Peptide and Phosphodiesterase 4D Levels in Adults With Overt Hypothyroidism: A Case-Control Study. | Cureus | 2026 | 42732212 | PubTator, text mining | PubMed |
| Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis. | Inflammopharmacology | 2026 | 42726435 | PubTator, text mining | PubMed |
| Exploring the molecular mechanisms of Weifuchun in the treatment of chronic atrophic gastritis based on single-cell sequencing and machine learning. | J Ethnopharmacol | 2026 | 42716194 | PubTator, text mining | PubMed |
| Berberine, a natural molecular glue degrader, overcomes CML resistance via TRIM28-mediated HIF1α ubiquitination and subsequent ferroptosis. | Cell Rep | 2026 | 42709544 | PubTator, text mining | PubMed |
| ATP/P2X7 signaling as a potential predictive biomarker for early recurrence of nasal polyps: Correlation with inflammasome activation and epithelial barrier dysfunction. | World Allergy Organ J | 2026 | 42707170 | PubTator, text mining | PubMed |
| A Comprehensive Review of Phosphodiesterases 4 (PDE4) Inhibitors in Clinical Trials. | Curr Pharm Des | 2026 | 42515906 | PubTator, text mining | PubMed |
| Therapeutic potential of pachymic acid in glioma: a comprehensive approach combining experimental validation, network pharmacology, and machine learning. | Brain Res | 2026 | 42468874 | PubTator, text mining | PubMed |
| Design, Synthesis, and Evaluation of Braylin Derivatives as Novel PDE4 Inhibitors with Anti-Inflammatory Effects. | Pharmaceutics | 2026 | 42198210 | PubTator, text mining | PubMed |
1 to 10 of 2,257
See all 2,257 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5144
GET https://conductscience.org/api/genes/v1/5144/patents?page=2